1. 3403 Final overall survival (OS) analysis of the randomized phase 3 study of trabectedin (T) or dacarbazine (D) for the treatment of patients (pts) with advanced leiomyosarcoma (LMS) or liposarcoma (LPS). (September 2015) Authors: Patel, S.; Mehren, M. Von; Reed, D.; Agulnik, M.; Kaiser, P.; Charlson, J.; Kraft, A.; Hamm, J.; Karnad, A.; Ryan, C.; Rushing, D.; Meyer, C.; Khokhar, N.Z.; McCarthy, S.; Park, Y.C.; Knoblauch, R.E.; Parekh, T.V.; Maki, R.G.; Demetri, G.D. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S689 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗